Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671534 · ClinicalTrials.gov registry record · Phase 2
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
A Phase 2 study, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07671534 is a Phase 2 study that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 60 participants.
The verdict
NCT07671534, a Phase 2 study, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
Interventions
- DRUG Gemcitabine
- DRUG Mitomycin C
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07671534
The ClinicalTrials.gov registry entry for NCT07671534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT07671534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07671534 about?
NCT07671534 is a clinical study titled "Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors". This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
What is the current status of trial NCT07671534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07671534?
The interventions under investigation include: Gemcitabine (DRUG), Mitomycin C (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT07671534?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.